Thin Film Electronics ASA
Oslo, 25 March 2021
Reference is made to the announcement by Thin Film Electronics ASA (the "Company") on 20 May 2020 regarding an Extraordinary General Meeting where the shareholders resolved to issue warrants to participants in a Private Placement and Subsequent Offering of shares, and on 30 June 2020 regarding the result of the Subsequent Offering.
The Company has received further notices of exercise for a total of 58,680,765 Warrants B and has subsequently resolved to increase the Company's share capital by NOK 6,454,884.15 in connection with the issuance of shares upon said exercises. Upon registration of this share capital increase, the Company's share capital will be NOK 128,571,605.58 divided into 1,168,832,778 shares, each share having a par value of NOK 0.11.
Contact:
Ståle Bjørnstad - Investor Relations
E-mail: stale.bjornstad@thinfilmsystems.com
Phone: +47 99 16 76 72
Kevin Barber - CEO
E-mail: kevin.barber@thinfilmsystems.com
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
FLSmidth A/S9.7.2025 08:41:33 CEST | Press release
Correction to Company Announcement no. 15-2025: Transactions under share buy-back programme
Syensqo SA9.7.2025 08:30:00 CEST | Press release
Syensqo - Participation notification by BlackRock Inc.
Sparekassen Sjælland-Fyn A/S9.7.2025 08:13:26 CEST | Pressemeddelelse
SJF Bank opjusterer forventningerne til resultatet for 2025
Ekopak N.V.9.7.2025 08:10:24 CEST | Press release
Ekopak appoints Jean-Baptiste De Cuyper as new CEO
Purespring Therapeutics9.7.2025 08:00:00 CEST | Press release
Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom